(MedPage Today) -- The novel amyloid plaque-targeted biologic drug solanezumab failed to demonstrate benefit for treating Alzheimer's disease, but a slight signal of efficacy in a subset of patients may breathe new life into the drug. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment